Farrah J. Mateen, MD, PhD is an Associate Professor of Neurology at Harvard Medical School.
She is originally from Saskatchewan, Canada where she received her medical degree (2005). She pursued adult neurology training at the Mayo Clinic in Minnesota (American Board of Psychiatry and Neurology, 2009) and a Fellowship in Medical Ethics at Harvard University (2008). Dr. Mateen's clinical and research fellowship training in neuroimmunology and neurological infections was at the Johns Hopkins Hospital (2012), supported by the American Brain Foundation. Dr. Mateen completed her doctoral studies in International Health at the Johns Hopkins University (2014) as a Sommer Scholar.
Dr. Mateen's clinical practice is dedicated to multiple sclerosis and neuromyelitis optica where she enjoys seeing patients with diagnostically and therapeutically complex conditions. She is interested in longterm safety and emerging therapies for MS and NMO. She also performs research on MS, NMO, and related demyelinating diseases including radiologically isolated syndrome (RIS).
Dr. Mateen is principal investigator of the Guinea Epilepsy Project, a multi-country study of a smartphone-based electroencephalogram (EEG) and the MAMBO trial (Measuring Ambulation Motor and Behavioral Outcomes) in Tanzania, funded through the of the National Institutes of Health and others. She has a sustained interest in neurological disorders in refugees and asylum seekers.
Dr. Mateen is a current member and past chair of the American Neurological Association's International Outreach Committee and of the American Academy of Neurology's Global Health Section (2014-2016) and Ethics Section (2011-2013). She is a member of the AAN Working Group on Refugees and Asylum Seekers and on the steering committee of trims.online. She has worked with the UN High Commissioner for Refugees, World Health Organization, Polio Eradication Initiative, and several NGOs. Her work includes collaborations throughout Africa, Asia, the Middle East, and South America. Dr. Mateen has published >150 academic manuscripts to advance neurological disease research and clinical care.